You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仟源醫藥(300254.SZ):上半年預虧7200萬元~7700萬元
格隆匯 07-14 18:12

格隆匯 7 月 14日丨仟源醫藥(300254.SZ)公告,預計上半年虧損:7,200萬元~7,700萬元,上年同期盈利:4,213.13萬元,比上年同期變動:-270.89%~-282.76%。

業績變動原因:

1、報告期內受新冠肺炎疫情影響,公司抗感染藥物及呼吸系統藥物等產品的銷售收入下降幅度較大。

2、公司主要產品美洛西林鈉舒巴坦鈉、阿莫西林鈉舒巴坦鈉等退出了2019版《國家醫保目錄》,上述產品佔公司營業收入比重較大,報告期內上述產品營業收入同比降幅較大。

3、報告期內西藏仟源收到了1,000萬元的產業發展扶持基金,而2019年上半年度西藏仟源則收到了3,100萬元的產業發展扶持基金,導致公司營業外收入同比下降較大。

4、2019年11月,公司與江蘇疌泉醴澤健康產業創業投資基金(有限合夥)(以下簡稱“醴澤基金”)及自然人張宇簽署《關於投資江蘇嘉逸醫藥有限公司之合作協議》,共同設立南通恆嘉藥業有限公司受讓江蘇嘉逸醫藥有限公司的部分股權。協議約定公司對醴澤基金、張宇的出資款負有回購義務。因此,公司將醴澤基金、張宇對南通恆嘉藥業有限公司的出資作為金融負債,並按照約定的年化收益率計提相關金融負債產生的財務費用,導致報告期內利息支出增加約1,290萬元。

5、報告期內預計非經常性損益對淨利潤的影響約1,300萬元,主要是公司收到政府補助等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account